|1.||Manosuthi, Weerawat: 9 articles (01/2013 - 01/2007)|
|2.||Sungkanuparph, Somnuek: 9 articles (08/2011 - 01/2007)|
|3.||Fowler, Mary Glenn: 8 articles (03/2014 - 06/2006)|
|4.||Pirmohamed, Munir: 7 articles (04/2015 - 01/2006)|
|5.||Mofenson, Lynne M: 7 articles (03/2014 - 02/2004)|
|6.||Jackson, J Brooks: 7 articles (03/2014 - 04/2002)|
|7.||Musoke, Philippa: 7 articles (03/2014 - 02/2004)|
|8.||Chipato, Tsungai: 7 articles (03/2014 - 08/2006)|
|9.||Landriscina, Matteo: 7 articles (05/2009 - 05/2003)|
|10.||Beijnen, Jos H: 7 articles (07/2005 - 09/2002)|
01/01/2015 - "SJS/TEN is one of the most serious adverse reactions to Nevirapine (NVP) treatment, commonly used in developing countries as first-line treatment of human immunodeficiency virus infection. "
02/01/2014 - "Nevirapine is widely used for the treatment of HIV-1 infection; however, its chronic use has been associated with severe liver and skin toxicity. "
12/01/2005 - "In many places, the only available option is single-dose nevirapine to mother and baby, which is effective in halving transmission risk, although the effectiveness in practice will be influenced by continued infection through breastfeeding, and by program factors such as the uptake of HIV testing. "
09/01/2003 - "Nevirapine-containing regimens are effective in patients with advanced HIV-1 infection, i.e., low CD4+ cell counts. "
01/01/2010 - "This study suggests that the nevirapine-based antiretroviral therapy could be used safely as first-line treatment in patients with low CD4 cell count in Africa despite frequent coinfections with HBV or HCV and infrequent testing of these infections. "
|2.||HIV Infections (HIV Infection)
10/01/2014 - "Efficacy of single dose Nevirapine in reducing viral load in HIV positive mother in labour and transmission of HIV infection to new born babies as part of prevention of parent to child transmission."
09/01/2000 - "In addition, preliminary clinical trial data suggest that nevirapine adds to the efficacy of combination therapy for the treatment of HIV infection in infants and children, and is reasonably well tolerated."
01/01/2013 - "Electronic databases (PubMed, EMBASE, the Cochrane Library, Trip Database) were searched up to 28 December 2012 for randomized controlled trials (RCTs) published as a full text and regarding nevirapine-based regimens used as a initial treatment for HIV infection. "
01/01/2012 - "We used data from the Six Week Extended Nevirapine (SWEN) trial to compare the growth patterns of HIV-infected and HIV-exposed but uninfected infants accounting for timing of HIV infection, and to identify risk factors for stunting, underweight and wasting. "
05/01/2009 - "This study was undertaken to assess the differences in the pharmacokinetics of nevirapine between patients with HIV/HCV coinfection and HIV infection that could explain higher rates of hepatotoxicity. "
|3.||Acquired Immunodeficiency Syndrome (AIDS)
08/01/2000 - "In an advancement that promises to significantly reduce the incidence of AIDS in children in developing countries, scientists have found a simple new way with nevirapine to prevent mother-to-child transmission of the AIDS virus that also is less costly and markedly more effective than the standard therapy with AZT in the third world. "
09/01/2005 - "Nevirapine derivatives with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS."
04/01/2009 - "At the time of the study, women did not have access to antiretroviral drugs for treatment of acquired immunodeficiency syndrome but had received nevirapine prophylaxis to reduce the risk of MTCT of HIV-1. "
01/01/2009 - "The study included all HIV/AIDS patients being treated with nevirapine-containing regimens. "
06/01/2007 - "The objective of the study was to determine the predisposing factors and incidence of toxicity among AIDS patients treated with a nevirapine (NVP)-based regimen in clinical practice. "
07/31/2012 - "Further studies are needed to define the pharmacokinetics, safety and efficacy of adjusted doses of nevirapine-based ART in young children with tuberculosis."
01/01/2015 - "Nevirapine concentrations at the end of the first week of treatment (on antituberculosis drugs) did not differ from concentrations off tuberculosis treatment, but declined thereafter. "
05/01/2013 - "Multivariable Cox regression controlled for age, sex, baseline immunologic category, baseline clinical category, baseline viral load, nutritional status, NRTIs used, receipt of single-dose nevirapine, and treatment for tuberculosis. "
04/01/2013 - "ART and tuberculosis: the final nail in nevirapine's coffin?"
07/31/2012 - "Predose concentrations of nevirapine were less than 3.0 mg/l in 11 children on tuberculosis treatment versus none of the 16 children without tuberculosis treatment (P = 0.001). "
08/01/2011 - "The genome-wide association analysis and replication studies of candidate SNPs identified significant associations of nevirapine-induced rash with 2 SNPs (rs1265112 and rs746647) within CCHCR1 on chromosome 6p21.3 (P(GWAS) = 1.6 × 10(-4); P(replication) = 2.6 × 10(-5); P(combined) = 1.2 × 10(-8)). "
01/01/2010 - "The study of the mechanistic steps leading to nevirapine-induced skin rash has been facilitated by the discovery of an animal model in which nevirapine causes a skin rash in rats that closely mimics the rash reported in patients. "
12/01/2009 - "In the present study, we investigated the specificity of lymphocytes in nevirapine-induced skin rash. "
12/01/2009 - "A study of the specificity of lymphocytes in nevirapine-induced skin rash."
01/01/2009 - "This study suggests that HLA-Cw*04 is associated with rash in nevirapine treated Thais. "
|9.||RNA-Directed DNA Polymerase (Reverse Transcriptase)
|10.||Protease Inhibitors (Protease Inhibitor)
|1.||Highly Active Antiretroviral Therapy (HAART)
|2.||Cesarean Section (Caesarean Section)
|5.||Drug Therapy (Chemotherapy)